Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Takeda Pharmaceutical : Announcement of decision on a basic plan for a merger (simple merger/short-form merger) with a wholly owned subsidiary

share with twitter share with LinkedIn share with facebook
09/24/2020 | 04:40am EDT

Osaka, Japan, September 24, 2020 --- Takeda Pharmaceutical Company Limited (Head Office: Chuo‑ku, Osaka; (TSE:4502/NYSE:TAK), 'Takeda') decided today on a basic plan for the implementation of an absorption-type merger (the 'Merger') of Takeda Pharmaceutical Real Estate Company, which is Takeda's wholly‑owned subsidiary. This decision is in line with Takeda's strategy of simplifying its legal entity ownership structure and establishing an agile operating model.

Please note that, because the Merger falls under the category of absorption-type merger (simple merger/short-form merger), with the disappearing company being Takeda's wholly‑owned subsidiary, this release is made in a simplified format.

Note

  1. Purpose of the Merger

Takeda has been promoting a company-wide legal entity rationalization to simplify its legal entity ownership structure, as well as to establish a simplified and agile operating model. As part of this, Takeda has made the decision on a basic plan to integrate Takeda Pharmaceutical Real Estate Company through the Merger to minimize complexity in Japan facility management and establish simplified and agile facility management operating model.

  1. Outline of the Merger

(i) Merger schedule
The date of Takeda's governance meeting decision on a basic plan for the Merger:
September 24, 2020

The scheduled date of the decision on the Merger by the director delegated by the board of directors' meeting: November 2020

The scheduled date of execution of the absorption-type merger agreement: December 2020

The scheduled effective date of the Merger: April 1, 2021

(ii) Method of the Merger
The Merger will be conducted as an absorption-type merger, with the surviving company being Takeda, and the disappearing company being Takeda Pharmaceutical Real Estate Company. Note that, for Takeda, the Merger falls under a simple merger as prescribed under Article 796, paragraph (2) of the Companies Act; and, for the disappearing company, a short-form merger as prescribed under Article 784, paragraph (1) of the Companies Act. Therefore, none of the above will go through a meeting of shareholders for approval of the absorption-type merger agreement.

(iii) Allotment upon the Merger
Since the Merger is an absorption-type merger with Takeda's wholly‑owned subsidiary, no issuance of new shares or allotment of monies or other properties will be conducted upon the Merger.

(iv) Handling of the disappearing company's share options and bonds with share options
Not applicable.

  1. Overview of the Parties of the Merger

Surviving company
(As of March 31, 2020)

Disappearing company
(As of March 31, 2020)

(1) Name

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Real Estate Company

(2) Address

1-1, Doshomachi 4‑chome, Chuo‑ku, Osaka‑shi, Osaka, Japan

1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan

(3) Title and name of the representative person

Representative Director, President & CEO:
Christophe Weber

President & Representative Director:
Yasuhisa Yamamoto

(4) Business description

Research & development, manufacturing, sales and marketing of pharmaceutical drugs

Selling and buying, management, leasing, etc. of real estate

(5) Capital amount

1,668,123 million yen

100 million yen

(6) Date of foundation/ incorporation

January 29, 1925

June 26, 2006

(7) Number of outstanding shares

1,576,373,908 shares

20,000 shares

(8) Fiscal year end

March 31

March 31

(9) Major shareholders and their shareholding percentage

ž・The Master Trust Bank of Japan, Ltd. (Trust account) 7.98%

・The Bank Of New York Mellon as Depositary Bank for Depositary Receipt Holders 5.39%

・Japan Trustee Services Bank, Ltd. (Trust account) 5.15%

・JP Morgan Chase Bank 385632 3.03%

・Nippon Life Insurance Company 2.24%

Takeda 100%

(10) Result of operations and financial conditions for the immediately preceding fiscal year

March 2020
(Consolidated, IFRS)

March 2020
(Non-consolidated, JGAAP)

Equity attributable to owners of the parent company / Net Assets

4,723,483 million yen

48,394 million yen

Total assets

12,821,094 million yen

55,268 million yen

Equity per share /Net assets per share

3,032.22 yen

2,419,706 yen

Total revenue

3,291,188 million yen

 -

Operating profit (loss)

100,408 million yen

799 million yen

Profit (loss) before tax

(60,754) million yen

1,202 million yen

Net profit attributable to owners of the parent company / Net profit (loss)

44,241 million yen

(1,014) million yen

Basic earnings per share / Net profit (loss) per share

28.41 yen

(50,679.48) yen

  1. Status after the Merger

There is no change in the name, address, title and name of the representative person, business description, capital amount, and fiscal year end of Takeda after the Merger.

  1. Business Outlook

Since the Merger is a merger with Takeda's consolidated subsidiary, the financial impact on the consolidated earnings is expected to be minimal.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Important Notice
For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could' 'anticipates', 'estimates', 'projects' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.

Investor Relations:
Christopher O'Reilly
takeda.ir.contact@takeda.com
+81 (0) 3-3278-2306

Media Contacts:
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Disclaimer

Takeda Pharmaceutical Co. Ltd. published this content on 24 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 September 2020 08:39:01 UTC


share with twitter share with LinkedIn share with facebook
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10/15Nikkei flat as coronavirus resurgence in Europe hits sentiment
RE
10/15Japan stocks fall as risks on several fronts unsettle investors
RE
10/14TAKEDA PHARMACEUTICAL : Accelerates Digital Transformation with Accenture and AW..
AQ
10/13TAKEDA PHARMACEUTICAL : - Safety and Efficacy of Subcutaneous Entyvio Sustained ..
AQ
10/13TAKEDA PHARMACEUTICAL : Accelerates Digital Transformation with Accenture and AW..
AQ
10/13TAKEDA PHARMACEUTICAL : Accelerates Digital Transformation with Accenture and AW..
BU
10/12Takeda group begins manufacturing COVID-19 plasma treatment ahead of approval
RE
10/12TAKEDA PHARMACEUTICAL : Safety and Efficacy of Subcutaneous Entyvio® (Vedolizuma..
BU
10/09GLOBAL MARKETS LIVE : Acquisitions, acquisitions, acquisitions
10/09Japan stocks post biggest weekly gain in 2 months on U.S. stimulus hopes
RE
More news
Financials
Sales 2021 3 267 B 30 953 M 30 953 M
Net income 2021 177 B 1 678 M 1 678 M
Net Debt 2021 3 935 B 37 278 M 37 278 M
P/E ratio 2021 42,5x
Yield 2021 5,04%
Capitalization 5 587 B 52 973 M 52 927 M
EV / Sales 2021 2,91x
EV / Sales 2022 2,64x
Nbr of Employees 47 495
Free-Float 99,1%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 443,85 JPY
Last Close Price 3 574,00 JPY
Spread / Highest target 81,9%
Spread / Average Target 52,3%
Spread / Lowest Target 14,7%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-17.50%52 973
JOHNSON & JOHNSON-1.06%389 921
ROCHE HOLDING AG-0.56%291 357
PFIZER INC.-3.14%210 884
MERCK & CO., INC.-13.50%201 909
NOVARTIS AG-14.09%190 074